Undisclosed α4β7 integrin inhibitor
/ C4X Discovery
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 22, 2025
C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme
(GlobeNewswire)
- "The selected candidate supports once-daily dosing and presents a potentially transformative oral therapy for IBD patients."
Pipeline update • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1